▲ +46.76% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Cortexyme in the last 3 months. The average price target is $50.00, with a high forecast of $76.00 and a low forecast of $20.00. The average price target represents a 46.76% upside from the last price of $34.07.
The current consensus among 7 polled investment analysts is to hold stock in Cortexyme. This rating has held steady since November 2020, when it changed from a Buy consensus rating.
Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's disease and other degenerative disorders. Its lead drug candidate is COR388, an orally-administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III for use in patients with mild to moderate Alzheimer's disease. The company was incorporated in 2012 and is headquartered in South San Francisco, California.